BD (Becton, Dickinson and Company) announced the successful completion of the spin-off of its Biosciences & Diagnostic Solutions business and its combination with Waters Corporation. BD shareholders will receive approximately 0.135 shares of Waters common stock for each BD share, and BD received $4 billion in cash, which it plans to use for share repurchases and debt repayment. This transaction marks the final milestone of BD’s “BD 2025 strategy,” positioning it as a focused MedTech company, and Dr. Claire M. Fraser has been appointed to the Waters Corporation Board of Directors.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
BD (Becton, Dickinson and Company) announced the successful completion of the spin-off of its Biosciences & Diagnostic Solutions business and its combination with Waters Corporation. BD shareholders will receive approximately 0.135 shares of Waters common stock for each BD share, and BD received $4 billion in cash, which it plans to use for share repurchases and debt repayment. This transaction marks the final milestone of BD’s “BD 2025 strategy,” positioning it as a focused MedTech company, and Dr. Claire M. Fraser has been appointed to the Waters Corporation Board of Directors.